FDA OMHHE Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH) (U01) Clinical Trials Optional
ID: 356052Type: Forecasted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$3M - $3M

Eligible Applicants

Unrestricted

Funding Category

Consumer Protection

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356052
Timeline
    Description

    The Food and Drug Administration (FDA) is forecasting a funding opportunity for the Health Equity Innovation Award: Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH), which will be administered as a cooperative agreement (U01). This initiative aims to enhance minority health and health equity through research, outreach, and communication efforts, while also providing training and mentorship for diverse students, fellows, and researchers. The program is critical for advancing health equity and addressing disparities in health outcomes among racial and ethnic minorities. Interested applicants can apply for a funding amount of $3 million, with an expected six awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or by phone at 240-402-7610. The opportunity is set for the fiscal year 2025, with no cost-sharing or matching requirements.

    Point(s) of Contact
    Terrin Brown Grantor
    (240) 402-7610
    terrin.brown@fda.hhs.gov
    Files
    No associated files provided.
    Similar Opportunities
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering the Health Equity Innovation Award (U01) to fund innovative research aimed at enhancing minority health and advancing health equity objectives. This funding opportunity focuses on proposals that promote diversity in clinical trials, improve data availability on diverse populations, and amplify the voices of underrepresented patient groups. With an award ceiling of $1 million and a floor of $250,000, the FDA anticipates making four awards in fiscal year 2024. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a funding opportunity titled "FDA OMHHE Health Equity Innovation Award: Enhance Equity Funding Opportunity (U01)," aimed at advancing minority health and health equity objectives. This cooperative agreement seeks innovative research proposals that enhance diversity in clinical trials, improve data availability on diverse populations, and amplify diverse patient perspectives and needs. The initiative is crucial for addressing disparities in health outcomes and ensuring equitable representation in health research. Interested applicants can apply for a funding amount of $1 million, with an expected four awards to be made, and should direct inquiries to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610. The opportunity is set for the fiscal year 2025 and was last updated on August 14, 2024.
    FDA OMHHE Convener for Racial & Ethnic minority Acceleration Consortium for Health Equity (REACH)
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "FDA OMHHE Convener for Racial & Ethnic Minority Acceleration Consortium for Health Equity (REACH)." This initiative aims to support a convener for the REACH consortium, which will consist of 5-8 multi-project cooperative agreement awardees focused on advancing minority health and health equity by facilitating communication, research, and collaboration on health issues disproportionately affecting racial and ethnic minority populations. The selected convener will be responsible for coordinating data integration, analysis, and visualization, as well as managing workshops and collaborations among REACH investigators. Interested applicants, particularly small businesses, can reach out to Shashi Malhotra at shashi.malhotra@fda.hhs.gov or call 240-402-7592 for further details. The estimated synopsis post date is January 3, 2023, with a closing date anticipated on March 3, 2023, and the funding opportunity falls under the category of discretionary grants with no cost-sharing requirements.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a funding opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This cooperative agreement aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) initiatives by promoting education, outreach, and public awareness regarding the use and potential risks associated with skin lightening products, such as hydroquinone. The funding is crucial for developing innovative, community-based strategies that will strengthen the scientific foundation for public health education on this topic. Interested applicants can apply for a funding amount of $250,000, with the opportunity forecasted for fiscal year 2025. For further inquiries, applicants may contact Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610.
    OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is offering a grant opportunity titled "OMHHE Educational Funding Opportunity: Expanding education on skin lightening products (U01) Clinical Trials Not Allowed." This initiative aims to enhance the FDA's Office of Minority Health and Health Equity (OMHHE) efforts by funding research and community-based strategies that promote education and public awareness regarding the risks associated with over-the-counter skin lightening products containing hydroquinone and/or mercury. The grant, which has a fixed award amount of $250,000, is open to unrestricted applicants and is part of the fiscal year 2024 funding cycle. Interested parties can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further information.
    NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the Racial Equity Visionary Award Program to support innovative research addressing substance use disparities among underserved racial and ethnic minority groups. This funding opportunity invites early career and established scholars from domestic minority-serving institutions to submit proposals that challenge existing scientific paradigms and aim for transformative impacts in health equity. NIDA plans to allocate approximately $2 million annually for 2-3 awards, with each application budget capped at $700,000 for projects lasting up to five years. Interested applicants must adhere to NIH guidelines and submit their proposals by November 14, 2024, with further inquiries directed to OERWebmaster03@od.nih.gov.
    NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions." This initiative invites R01 applications aimed at conducting impactful research to address disparities in substance use and addiction outcomes among racial and ethnic minority populations, emphasizing community engagement and collaboration with community organizations. The program is part of NIDA's broader Racial Equity Initiative, which seeks to improve health equity and reduce health disparities, with approximately $2 million anticipated for funding across multiple related announcements. Interested applicants, particularly from minority-serving institutions, must submit proposals by November 14, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities," aimed at supporting intervention research to improve health outcomes among minority populations affected by health disparities. The initiative seeks projects that investigate the influence of structural racism and discrimination on health determinants, promote multidisciplinary collaboration, and utilize diverse data sources for comprehensive analysis. With a funding ceiling of $500,000, the application deadline is set for January 7, 2026, and interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines
    Active
    Food and Drug Administration
    The Food and Drug Administration (FDA) is forecasting a cooperative agreement opportunity titled "Cooperative Agreement to Support Effective Dissemination of Clinical Practice Guidelines." This initiative aims to support the dissemination of clinical practice guidelines, particularly those developed with prior FDA cooperative agreements, by requiring applicants to propose a comprehensive plan for developing, evaluating, and distributing materials that facilitate this dissemination, with a strong emphasis on equity. The funding for this opportunity has an award ceiling and floor of $1,000,000, with one award expected to be made in fiscal year 2025. Interested applicants can reach out to Terrin Brown at terrin.brown@fda.hhs.gov or call 240-402-7610 for further details.
    NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research," aimed at supporting R01 applications that focus on community-partnered research to mitigate disparities in substance misuse and health outcomes among racial and ethnic minority populations. This initiative emphasizes the establishment of collaborative community partnerships to ensure that research addresses immediate community needs and employs effective methodologies, thereby advancing health equity in the context of substance use and addiction. The program has a budget of approximately $2 million for FY 2023, with applications due by November 14, 2024. Interested applicants can find more information and application instructions at the provided link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.